Kynurenine pathway profiles as markers of ketamine response in treatment-resistant depression.
Brain, Behavior, and Immunity July 5, 2026 Bruno Pedraz-Petrozzi, Marta Marszalek-Grabska, Emilia Fornal et al.
Treatment-resistant depression (TRD) remains a major clinical challenge, with highly variable responses to ketamine. Immune activation characterizes a subset of patients with TRD. The kynurenine pathway (KP), which integrates immunometabolic signals with glutamatergic neurotransmission, may provide candidate biomarkers to inform personalized treatment. We investigated whether KP metabolites and...
DOI: 10.1016/j.bbi.2026.106889 (opens in new tab)
Full text (opens in new tab)
Ketamine
Treatment-resistant depression
Immunometabolic depression
Kynurenic acid
+1